Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

19Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). Patients and Methods: Adults with advanced/metastatic EGFR-mutant NSCLC, acquired resistance to first-/second-generation EGFR inhibitors, and MET gene copy number (GCN) ≥5, MET: CEP7 ≥2, or MET IHC 2þ/3þ were randomized to tepotinib 500 mg (450 mg active moiety) plus gefitinib 250 mg once daily, or chemotherapy. Primary endpoint was investigator-assessed progression-free survival (PFS). MET-amplified subgroup analysis was preplanned. Results: Overall (N ¼ 55), median PFS was 4.9 months versus 4.4 months [stratified HR, 0.67; 90% CI, 0.35–1.28] with tepotinib plus gefitinib versus chemotherapy. In 19 patients with MET amplification (median age 60.4 years; 68.4% never-smokers; median GCN 8.8; median MET/CEP7 2.8; 89.5% with MET IHC 3þ), tepotinib plus gefitinib improved PFS (HR, 0.13; 90% CI, 0.04–0.43) and overall survival (OS; HR, 0.10; 90% CI, 0.02–0.36) versus chemotherapy. Objective response rate was 66.7% with tepotinib plus gefitinib versus 42.9% with chemotherapy; median duration of response was 19.9 months versus 2.8 months. Median duration of tepotinib plus gefitinib was 11.3 months (range, 1.1–56.5), with treatment >1 year in six (50.0%) and >4 years in three patients (25.0%). Seven patients (58.3%) had treatment-related grade ≥3 adverse events with tepotinib plus gefitinib and five (71.4%) had chemotherapy. Conclusions: Final analysis of INSIGHT suggests improved PFS and OS with tepotinib plus gefitinib versus chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC, after progression on EGFR inhibitors.

References Powered by Scopus

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

2033Citations
N/AReaders
Get full text

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

883Citations
N/AReaders
Get full text

Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations

616Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

13Citations
N/AReaders
Get full text

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

12Citations
N/AReaders
Get full text

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Liam, C. K., Ahmad, A. R., Hsia, T. C., Zhou, J., Kim, D. W., Soo, R. A., … Wu, Y. L. (2023). Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research, 29(10), 1879–1886. https://doi.org/10.1158/1078-0432.CCR-22-3318

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Lecturer / Post doc 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 4

36%

Engineering 3

27%

Medicine and Dentistry 2

18%

Biochemistry, Genetics and Molecular Bi... 2

18%

Article Metrics

Tooltip
Mentions
News Mentions: 3

Save time finding and organizing research with Mendeley

Sign up for free